PARIS: French healthcare group Sanofi has agreed to buy US haemophilia specialist Bioverativ for US$11.6bil, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases.
Sanofi shares fell 3.4% by 0920 GMT, making the stock the worst performer on France’s benchmark CAC-40 index and several analysts deemed the deal expensive.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
